Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences

SAN DIEGO,Calif.,and SUZHOU and SHANGHAI,China,Nov. 23,2022 -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"),a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer,today announced that the management team will participate in and attend one-on-one meetings at two upcoming investor conferences.

Piper Sandler 34th Annual Healthcare Conference

Presentation: November 30th at 4:00 pm ET

One-on-one meetings: Wednesday,November 30,2022

Location: New York,NY

JMP Securities Hematology & Oncology Summit (virtual)

Presentation: December 7th at 10:00 am ET

One-on-one meetings: December 6 - 7,2022

Webcast of the fireside chat will be available on the News and Eventssection of Gracell's investor website. A replay of the webcast will be available for 30 days following the event.

About Gracell

Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms and SMART CARTTM technology module,Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies,including lengthy manufacturing time,suboptimal cell quality,high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell,please visit www.gracellbio.com. Follow @GracellBio on LinkedIn.

Media contact

Marvin Tang

marvin.tang@gracellbio.com

Investor contact

Gracie Tong

gracie.tong@gracellbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/gracell-biotechnologies-to-participate-in-two-upcoming-investor-conferences-301685858.html